Breakout Labs support a portfolio of early-stage companies in areas ranging from food science and biomedicine to clean energy.
Key people at Breakout Labs.
# Breakout Labs: Funding the Radical Science That Venture Capital Overlooks
Breakout Labs operates as a nonprofit seed-stage fund and accelerator within the Thiel Foundation, dedicated to catalyzing early-stage startups working at the intersection of technology, biology, materials, and energy.[1][2] The organization's mission centers on reshaping how early-stage science gets funded—specifically by backing companies pursuing ideas considered too speculative, radical, or long-term to attract traditional venture capital or angel investors, yet too commercially oriented for conventional scientific research funding.[1]
The investment philosophy is distinctly contrarian: rather than waiting for market validation, Breakout Labs identifies scientist-entrepreneurs with novel hypotheses that could unlock tremendous opportunity and impact at scale.[4] The firm focuses on deep science across three primary sectors: human health and biomedicine, sustainability and clean energy, and advanced materials and chemistry.[1][3] Since its inception, Breakout Labs has backed over 30 companies and has become a crucial bridge in the startup ecosystem—identifying and nurturing breakthrough science before it becomes attractive to mainstream venture capital.[2]
Breakout Labs launched in November 2011 as a program of the Thiel Foundation, the philanthropic organization created by billionaire Peter Thiel.[1] The program emerged from a specific insight: transformational scientific breakthroughs often require patient capital willing to fund research that traditional investors dismiss as too risky or too far from commercialization. The founders recognized a funding gap for scientist-entrepreneurs working on radical ideas that didn't fit neatly into either the venture capital or academic research funding models.
The organization announced its first batch of grantees on April 17, 2012, followed by a second batch in August 2012 and a third in April 2013.[1] These early cohorts validated the model—Breakout Labs issued convertible grants for early-stage commercialization of scientific research, creating a pipeline of promising companies. This success led to a natural evolution: in 2016, Breakout Ventures was founded as a separate entity to provide traditional venture capital investments in science-driven companies, leveraging the Breakout Labs grant program as a mechanism to identify investment opportunities.[1] This dual structure—grants for early exploration, equity for scaling—became the organization's defining characteristic.
Breakout Labs operates a two-tiered funding approach that few venture firms replicate. The organization begins with convertible grants for companies at the earliest stages—when ideas are still speculative and unproven. This grant-first model allows founders to validate hypotheses without immediately surrendering equity, reducing founder dilution and enabling more radical bets. Once companies demonstrate traction, Breakout Ventures steps in with traditional Series A and Series B capital.[1]
The firm's team has spent over a decade supporting science-driven companies, building institutional knowledge across biology, chemistry, and physics-based innovation.[4] Financial partners include heavyweight venture firms like Founders Fund, Formation 8, OATV, Lux Capital, and Khosla Ventures, providing portfolio companies with access to a sophisticated network of technical advisors, industry experts, and follow-on investors.[1]
Breakout Labs has formalized partnerships that amplify founder support. In 2017, the organization partnered with Science Exchange, the leading enterprise platform for outsourced R&D, to provide portfolio companies with access to external research innovation and laboratory resources.[2] This removes friction from the scientific development process and accelerates time-to-validation.
Rather than clustering around a single technology trend, Breakout Labs maintains a genuinely diversified portfolio spanning cancer immunotherapy (Noetik), clinical diagnostics (Cytovale), carbon transformation (Twelve), sustainable materials (Ecovative Design, Checkerspot), neurotechnology (Phantom Neuro, Shiratonics), and RNA therapeutics (EnPlusOne Bio).[3][4] This breadth reflects the organization's commitment to backing transformational science wherever it emerges.
Breakout Labs occupies a critical but often overlooked position in the innovation ecosystem. The organization sits at the intersection of three major trends: the convergence of biology, chemistry, and technology; the growing recognition that climate and health crises require scientific breakthroughs rather than incremental software improvements; and the maturation of deep tech as a legitimate venture category.
The timing has proven prescient. Over the past decade, venture capital has gradually shifted toward funding harder science—but Breakout Labs was already there, having backed companies years before deep tech became fashionable. This early positioning means the organization's portfolio companies often have first-mover advantages and deeper scientific moats than competitors funded later by generalist VCs.
More broadly, Breakout Labs influences the ecosystem by legitimizing radical science as venture-fundable. By demonstrating that companies pursuing novel hypotheses in biology, materials, and energy can achieve venture-scale returns, the organization has helped shift capital allocation across the entire venture landscape. The success of portfolio companies like Ecovative Design (mycelium-based materials) and Modern Meadow (biofabrication) has shown other investors that deep science isn't just academically interesting—it's commercially viable.
Breakout Labs has successfully proven that patient capital applied to radical science can generate both impact and returns. As climate change, pandemic preparedness, and healthcare costs intensify, the organization's focus areas—sustainable materials, advanced therapeutics, clean energy—will only become more strategically important.
The future trajectory likely involves continued expansion of the portfolio across emerging deep tech domains, particularly at the intersection of AI and biology (already evident in portfolio companies like Noetik and A-Alpha Bio). The organization may also see increased institutional capital flowing through Breakout Ventures as limited partners recognize that the best deep tech investments often come from firms with decade-long track records in identifying breakthrough science.
What makes Breakout Labs enduring is its fundamental insight: the most transformational innovations often look too risky to traditional investors. By maintaining conviction in radical science and providing patient capital when others won't, Breakout Labs has become an essential institution for the next generation of breakthrough founders—and a model for how venture capital can drive progress on humanity's hardest problems.
Key people at Breakout Labs.
